Ylated (52) U.S

Total Page:16

File Type:pdf, Size:1020Kb

Load more

US 2015036.1099A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0361099 A1 COUGHLN et al. (43) Pub. Date: Dec. 17, 2015 (54) PROCESSES FOR MAKING ALKYLATED (52) U.S. Cl. ARYLPPERAZINE AND ALKYLATED CPC ............ C07D 519/00 (2013.01); C07D 417/08 ARYLPPERDINE COMPOUNDS (2013.01); C07D 261/20 (2013.01); C07D INCLUDING NOVELINTERMEDIATES 209/56 (2013.01); C07D 417/12 (2013.01); C07D 215/227 (2013.01); C07D401/12 (71) Applicant: Johnson Matthey Public Limited (2013.01); C07D 403/12 (2013.01); C07D Company, London (GB) 275/06 (2013.01); C07D 311/20 (2013.01); C07D 413/12 (2013.01) (72) Inventors: Daniel J. COUGHILIN, Mullica Hill, NJ (US); Jeremy C. Wilt, Marlborough, MA (US); Da-Ming GOU, Burlington, (57) ABSTRACT MA (US) Novel processes, and intermediates, for making alkylated (21) Appl. No.: 14/737,599 arylpiperazine and alkylated arylpiperidine compounds of the general formulas (I) and (VII), respectively (22) Filed: Jun. 12, 2015 Related U.S. Application Data (I) (60) Provisional application No. 62/012,701, filed on Jun. 16, 2014. y - N-Air, Publication Classification R R2 (51) Int. Cl. (VII) C07D 519/00 (2006.01) CO7D 26L/20 (2006.01) C07D 209/56 (2006.01) C07D 417/12 (2006.01) R R2 CO7D 413/2 (2006.01) CO7D 40/12 (2006.01) CO7D 403/2 (2006.01) wherein, R and R are individually selected from hydrogen, C07D 275/06 (2006.01) alkyl, substituted or alkyl; n=0, 1, or 2: Y-NRR, ORs, or CO7D 3L/20 (2006.01) SRs, where R and Ra are individually selected from acyl or CO7D 417/08 (2006.01) sulfonyl, and where Rs is aryl or heteroaryl, or heterocyclic; C07D 215/227 (2006.01) and Ar is an aryl, heteroaryl, or heterocyclic compound. US 2015/0361099 A1 Dec. 17, 2015 PROCESSES FOR MAKING ALKYLATED ARYLPPERAZINE AND ALKYLATED (I) ARYLPPERDINE COMPOUNDS INCLUDING NOVELINTERMEDIATES Y ( N NHAir CROSS-REFERENCE TO RELATED ) (TV / APPLICATIONS R R 0001. This application claims priority of U.S. Provisional (VII) Patent Application No. 62/012,701, filed Jun. 16, 2014, the disclosures of which are incorporated herein by reference in their entireties for all purposes. R R2 FIELD OF THE INVENTION 0002 The present disclosure provides processes for mak wherein, R and R are individually selected from hydrogen, ing alkylated arylpiperazine and alkylated arylpiperidine unsubstituted alkyl, and Substituted alkyl, or R and R2 are compounds as well as novel intermediate compounds formed connected to form a 5 to 8 carbon cyclic ring; n is 0, 1, or 2; during those processes. Y is NRR, ORs, or SRs, where R and R are individually selected from acyl or Sulfonyl, wherein R and R may be BACKGROUND OF THE INVENTION connected to form a substituted or unsubstituted cyclic or 0003. The piperazines are a broad class of chemical com bicyclic ring, and wherein Rs is aryl or heteroaryl, or hetero pounds, many with important pharmacological properties, cyclic; and Ar is an aryl or heteroaryl group. which contain a core piperazine functional group. Many cur 0007 Novel intermediate compounds, made during the rently notable pharmaceutical drugs contain a piperazine ring processes described and claimed herein, are also disclosed. as part of their molecular structure. Examples include: anti anginals (ranolazine, trimetazidine); antidepressants (amox BRIEF DESCRIPTION OF THE DRAWINGS apine, befuraline, buspirone, flesinoxan, gepirone, ipsa 0008 No drawings. pirone, nefazodone, piberaline, tandospirone, traZodone, villazodone, Zalospirone); antihistamines (buclizine, mecloz DETAILED DESCRIPTION OF THE INVENTION ine, cinnarizine, cyclizine, hydroxy Zine, cetirizine, levoceti rizine, niaprazine); antipsychotics (fluphenazine, perphena Definitions Zine, trifluoperazine, prochlorperazine, thiothixene, 0009. Unless otherwise stated, the following terms used in flupentiXol, Zuclopenthixol, amperozide, aripiprazole, lurasi this application, including the specification and claims, have done, clozapine, olanzapine, peroSpirone, Ziprasidone); uro the definitions given below. It must be noted that, as used in logicals (sildenafil. Vardenafil). the specification and the appended claims, the singular forms 0004 Piperidine is also widely used building block and “a”, “an and “the include plural referents unless the context chemical reagent in the synthesis of organic compounds, clearly dictates otherwise. including pharmaceuticals. Similar to piperazine, piperidine 0010 All numerical designations, such as, weight, pH, and its derivatives are ubiquitous building blocks in the Syn temperature, time, concentration, and molecular weight, thesis of pharmaceuticals and fine chemicals. For example, including ranges, are approximations which are varied by the piperidine structure is found in the following classes of 10%. It is to be understood, although not always explicitly pharmaceuticals: SSRI (selective serotonin reuptake inhibi stated, that all numerical designations are preceded by the tors) (paroxetine); analeptics/nootropics (stimulants) (meth term “about.” It also is to be understood, although not always ylphenidate, ethylphenidate, pipradrol, desoxypipradrol); explicitly stated, that the reagents described herein are merely SERM (selective estrogen receptor modulators) (raloxifene); exemplary and that equivalents of Such are known in the art. vasodilators (minoxidil); neuroleptics (antipsychotics) (ris 0011. In reference to the present disclosure, the technical peridone, thioridazine, haloperidol, droperidol, and scientific terms used in the descriptions herein will have mesoridazine); opioids (pethidine, meperidine, loperamide). the meanings commonly understood by one of ordinary skill 0005 Considering their prevalence in the formation of a in the art, unless specifically defined otherwise. Accordingly, variety of important pharmaceutical compounds, there is a the following terms are intended to have the following mean need for new and improved processes for making both pip ings. erazine and piperidine compounds, including intermediates 0012 Compounds described herein can comprise one or and derivatives thereof, that minimizes the formation of more asymmetric centers, and thus can exist in various iso unwanted by-products and eliminates the need for additional meric forms, e.g., enantiomers and/or diastereomers. purification steps where product is lost. 0013 For example, the compounds described herein can be in the form of an individual enantiomer, diastereomer or SUMMARY OF THE INVENTION geometric isomer, or can be in the form of a mixture of 0006. The present disclosure provides processes for mak Stereoisomers, including racemic mixtures and mixtures ing alkylated arylpiperazine and alkylated arylpiperidine enriched in one or more stereoisomer. Isomers can be isolated compounds, including intermediates and derivatives thereof. from mixtures by methods known to those skilled in the art, More specifically, the present invention provides processes including chiral high pressure liquid chromatography for making a variety of alkylated arylpiperazine and alkylated (HPLC) and the formation and crystallization of chiral salts: arylpiperidine compounds of the general formulas (I) and or preferred isomers can be prepared by asymmetric synthe (VII), respectively, ses. The invention additionally encompasses compounds US 2015/0361099 A1 Dec. 17, 2015 described herein as individual isomers substantially free of eroaryl groups that contain one or more nitrogen atoms, the other isomers, and alternatively, as mixtures of various iso point of attachment can be a carbon or nitrogen atom, as CS. Valency permits. Heteroaryl bicyclic ring systems can include 0014 When a range of values is listed, it is intended to one or more heteroatoms in one or both rings. “Heteroaryl' encompass each value and Sub-range within the range. For includes ring systems wherein the heteroaryl ring, as defined example “C. alkyl is intended to encompass, C, C, C, above, is fused with one or more carbocyclic or heterocyclic C4. Cs. Co. C1-6. C1-s: C-4 C1-3. C1-2, C2-6. C2-s: C2-4 C2-3. groups wherein the point of attachment is on the heteroaryl C3-6. C3-5. C3-4 C4-6. C4. 53 and Cs-6 alkyl. ring, and in Such instances, the number of ring members 0015. As used herein, the term “alkyl means the monova continue to designate the number of ring members in the lent linear or branched Saturated hydrocarbon moiety, con heteroaryl ring system. “Heteroaryl also includes ring sys sisting solely of carbon and hydrogenatoms, having from one tems wherein the heteroaryl ring, as defined above, is fused to twelve carbon atoms. “Lower alkyl refers to an alkyl with one or more aryl groups wherein the point of attachment group of one to six carbonatoms, i.e., C-C alkyl. Examples is either on the aryl or heteroaryl ring, and in Such instances, of alkyl groups include, but are not limited to, methyl, ethyl, the number of ring members designates the number of ring propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl, members in the fused (arylheteroaryl) ring system. Bicyclic n-hexyl, octyl, dodecyl, and the like. “Branched alkyl heteroaryl groups wherein one ring does not contain a het means, for example, isopropyl, isobutyl, and tert-butyl. Spe eroatom (e.g., indolyl, quinolinyl, carbazolyl, and the like) cifically included within the definition of “alkyl are those the point of attachment can be on either ring, i.e., either the aliphatic hydrocarbon chains that are optionally Substituted. ring bearing a heteroatom (e.g., 2-indolyl) or the ring that 0016. As used herein, the term “alkylene' means a linear
Recommended publications
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts

    Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts

    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
  • Treatment of Psychosis: 30 Years of Progress

    Treatment of Psychosis: 30 Years of Progress

    Journal of Clinical Pharmacy and Therapeutics (2006) 31, 523–534 REVIEW ARTICLE Treatment of psychosis: 30 years of progress I. R. De Oliveira* MD PhD andM.F.Juruena MD *Department of Neuropsychiatry, School of Medicine, Federal University of Bahia, Salvador, BA, Brazil and Department of Psychological Medicine, Institute of Psychiatry, King’s College, University of London, London, UK phrenia. Thirty years ago, psychiatrists had few SUMMARY neuroleptics available to them. These were all Background: Thirty years ago, psychiatrists had compounds, today known as conventional anti- only a few choices of old neuroleptics available to psychotics, and all were liable to cause severe extra them, currently defined as conventional or typical pyramidal side-effects (EPS). Nowadays, new antipsychotics, as a result schizophrenics had to treatments are more ambitious, aiming not only to suffer the severe extra pyramidal side effects. improve psychotic symptoms, but also quality of Nowadays, new treatments are more ambitious, life and social reinsertion. We briefly but critically aiming not only to improve psychotic symptoms, outline the advances in diagnosis and treatment but also quality of life and social reinsertion. Our of schizophrenia, from the mid 1970s up to the objective is to briefly but critically review the present. advances in the treatment of schizophrenia with antipsychotics in the past 30 years. We conclude DIAGNOSIS OF SCHIZOPHRENIA that conventional antipsychotics still have a place when just the cost of treatment, a key factor in Up until the early 1970s, schizophrenia diagnoses poor regions, is considered. The atypical anti- remained debatable. The lack of uniform diagnostic psychotic drugs are a class of agents that have criteria led to relative rates of schizophrenia being become the most widely used to treat a variety of very different, for example, in New York and psychoses because of their superiority with London, as demonstrated in an important study regard to extra pyramidal symptoms.
  • Guaiana, G., Barbui, C., Caldwell, DM, Davies, SJC, Furukawa, TA

    Guaiana, G., Barbui, C., Caldwell, DM, Davies, SJC, Furukawa, TA

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Explore Bristol Research Guaiana, G., Barbui, C., Caldwell, D. M., Davies, S. J. C., Furukawa, T. A., Imai, H., ... Cipriani, A. (2017). Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews, 2017(7), [CD012729]. https://doi.org/10.1002/14651858.CD012729 Publisher's PDF, also known as Version of record Link to published version (if available): 10.1002/14651858.CD012729 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Cochrane Library at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012729/full . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms Cochrane Database of Systematic Reviews Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis (Protocol) Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A. Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews 2017, Issue 7.
  • Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication

    Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication

    King’s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD003382.pub3 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
  • Dopamine D2 Receptor Occupancy by Perospirone: a Positron Emission Tomography Study in Patients with Schizophrenia and Healthy Subjects

    Dopamine D2 Receptor Occupancy by Perospirone: a Positron Emission Tomography Study in Patients with Schizophrenia and Healthy Subjects

    Psychopharmacology (2010) 209:285–290 DOI 10.1007/s00213-010-1783-1 ORIGINAL INVESTIGATION Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects Ryosuke Arakawa & Hiroshi Ito & Akihiro Takano & Masaki Okumura & Hidehiko Takahashi & Harumasa Takano & Yoshiro Okubo & Tetsuya Suhara Received: 3 September 2009 /Accepted: 18 January 2010 /Published online: 27 March 2010 # Springer-Verlag 2010 Abstract striatum of healthy subjects was 74.8% at 1.5 h, 60.1% at Rationale Perospirone is a novel second-generation antipsy- 8 h, and 31.9% at 25.5 h after administration. chotic drug with high affinity to dopamine D2 receptor and Conclusion Sixteen milligrams of perospirone caused over short half-life of plasma concentration. There has been no 70% dopamine D2 receptor occupancy near its peak level, investigation of dopamine D2 receptor occupancy in patients and then occupancy dropped to about half after 22 h. The with schizophrenia and the time course of occupancy by time courses of receptor occupancy and plasma concentra- antipsychotics with perospirone-like properties. tion were quite different. This single dosage may be Objective We investigated dopamine D2 receptor occupan- sufficient for the treatment of schizophrenia and might be cy by perospirone in patients with schizophrenia and the useful as a new dosing schedule choice. time course of occupancy in healthy subjects. Materials and methods Six patients with schizophrenia Keywords Dopamine D2 receptor occupancy. taking 16–48 mg/day of perospirone participated. Positron Perospirone . Positron emission tomography . emission tomography (PET) scans using [11C]FLB457 were Schizophrenia . Time course performed on each subject, and dopamine D2 receptor occupancies were calculated.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • Exploring Pharmacological Significance and Reaction Dynamics of Piperazinemoiety

    Exploring Pharmacological Significance and Reaction Dynamics of Piperazinemoiety

    Exploring Pharmacological Significance and Reaction Dynamics of PiperazineMoiety. Rajashree A. Markandewar 1, S R Deshmukh 2 and M.A Baseer 3 1,2 Dept. of Chemistry, R. M. G.Mahavidyalaya, Saoli, Dist Chandrapur-441225 3Dept. of Chemistry, YeshwantMahavidyalaya, Nanded- 431602 Abstract: Piperazines and their analogs are amongst the most important backbones in today’s drug discovery industries. The purpose of this paper is to provide an overview of the pharmacological properties of piperazines and Reaction dynamics. The synthesis of of 4-(4- methyl piperazine-l-yl) benzaldehyde a variety of Nitrogen containing aldehyde is described with proper choice of base, solvent and temperature conditions. This work is underway to ameliorate difficulties which remain, especially in finding suitable reaction dynamics that efficiently increases the yield. The synthesized compounds were characterized by IR, 1HNMR and MS Spectroscopy. Keywords: Piperazines Nitrogen-containing-aldehyde, Reaction dynamics, N-arylation . Introduction: Synthetic chemistry provides corpucopia of heterocyclic systems. More than 90% of new drugs contain heterocycles and the interface between chemistry and biology. The modern day medicinal chemistry is based on heterocyclic molecules and we owe to them, due to their close association with numerous biological as well as pharmacological activities. Nitrogen containing heterocycles is subunit found in numerous natural products and in many biologically active pharmaceuticals [1]. An important aspect of medicinal chemistry is to establish as relationship between chemical structure and pharmacological activity. Piperazine is a sex membered ring structure containing twoopposing nitrogen atoms. Nitrogen containing compounds is used as structural components of pharmaceuticals and agrochemicals due to their high biological activities. There are many nitrogen containing chemicals, ranging from simple structural compounds as pyridine to complicated compounds as pharmaceuticals ingredients and their number is growing rapidly year by year [2].
  • Smoking Modulates Neuroendocrine Responses to Ipsapirone in Patients with Panic Disorder A

    Smoking Modulates Neuroendocrine Responses to Ipsapirone in Patients with Panic Disorder A

    Smoking Modulates Neuroendocrine Responses to Ipsapirone in Patients with Panic Disorder A. Broocks, M.D., Ph.D., B. Bandelow, M.D., Ph.D., K. Koch, U. Bartmann, J. Kinkelbur, M.D., U. Schweiger, M.D., Ph.D., F. Hohagen, M.D., Ph.D., and G. Hajak, M.D., Ph.D. Reduced 5-HT1A-receptor responsiveness has been reported temperature. In comparison to placebo, administration of in patients with panic disorder(PD) and/or agoraphobia ipsapirone was associated with significant increases of (PDA). Although many of these patients are regular various psychological symptoms and plasma cortisol smokers, it has not been examined whether psychological or concentrations. The subgroup of PD patients who were neurobiological effects induced by the selective 5-HT1A- smokers showed significantly higher cortisol responses to receptor agonist, ipsapirone, are affected by the smoking ipsapirone than non-smokers. status of the patients. In conclusion, smoking status has to be taken into In order to clarify this question neuroendocrine account when assessing the responsiveness of 5-HT1A challenges with oral doses of ipsapirone (0.3 mg/kg) and receptors in patients with psychiatric disorders. The placebo were performed in 39 patients with PDA, and prevention of smoking during challenge sessions might not results were compared between patients who smoked (Ͼ10 be the ideal approach in heavy smokers, since sudden cigarettes per day, n ϭ 17) and patients who had been non- abstinence from smoking is likely to affect neurobiological smokers for at least two years (n ϭ 22). and possibly psychological responses to ipsapirone. Patients who were smokers (but did not smoke during [Neuropsychopharmacology 27:270–278, 2002] the challenge procedure) had significantly reduced baseline © 2002 American College of Neuropsychopharmacology.
  • Customs Tariff - Schedule

    Customs Tariff - Schedule

    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
  • (12) United States Patent (10) Patent No.: US 6,319,953 B1 Carlson Et Al

    (12) United States Patent (10) Patent No.: US 6,319,953 B1 Carlson Et Al

    US006319953B1 (12) United States Patent (10) Patent No.: US 6,319,953 B1 Carlson et al. (45) Date of Patent: *Nov. 20, 2001 (54) TREATMENT OF DEPRESSION AND WO 95/08549 3/1995 (W0). ANXIETY WITH FLUOXETINE AND AN WO 95/18124 7/1995 (W0). NK-1 RECEPTOR ANTAGONIST W0 96/05181 2/1996 (W0). W0 96/18643 6/1996 (W0). (75) Inventors: Emma Joanne Carlson, Puckeridge; W0 96/19233 6/1996 (W0). Nadia Melanie Rupniak, Bishops W0 96/24353 8/1996 (W0). W0 98/15277 4/1998 (W0). Stortford, both of (GB) OTHER PUBLICATIONS (73) Assignee: Merck Sharp & Dohme Ltd., Hoddesdon (GB) Aguiar, M., et al., Physiology& Behavior, 1996, 60(4) 1183—1186. ( * ) Notice: Subject to any disclaimer, the term of this Barden, N., et al., J. Neurochem., 1983, 41, 834—840. patent is extended or adjusted under 35 BristoW, L., et al., Eur J. Pharmacol., 1994, 253, 245—252. U.S.C. 154(b) by 0 days. Brodin, E., et al., Neuropharmacology, 1987, 26(6) 581—590. This patent is subject to a terminal dis Brodin, E., et al., Neuropeptides, 1994, 26, 253—260. claimer. Culman, J., et al., J. Physiol. Pharmacol., 1995, 73, 885—891. Cutler, et al., J. Psychopharmacol, 1994, 8, A22, 87. (21) Appl. N0.: 09/457,241 Elliott, P. J., Exp. Brain Res. UK, 1988, 73, 354—356. (22) Filed: Dec. 8, 1999 F—D—C Reports—Prescription Pharmaceuticals and Bio technology, Dec. 8, 1997, 59(49), 10. Related US. Application Data File, S. E., Pharm. Biochem. Behavior, 1997, 58, 3, 747—752. (60) Division of application No.
  • Among a Series of Novel D4 Dopamine Receptor Agonists and Antagonists Jeremiah J

    Among a Series of Novel D4 Dopamine Receptor Agonists and Antagonists Jeremiah J

    Topographically Based Search for an “Ethogram” Among a Series of Novel D4 Dopamine Receptor Agonists and Antagonists Jeremiah J. Clifford, Ph.D., and John L. Waddington, Ph.D., D.Sc. The effects of three selective D4 antagonists [CP-293,019, 25.0 mg/kg) failed to influence any behavior; whereas, PD L-745,870, and Ro 61-6270] and two putative selective D4 168077 (0.2–25.0 mg/kg) induced nonstereotyped shuffling agonists [CP-226,269 and PD 168077] were compared with locomotion with uncoordinated movements, jerking, and those of the generic D2-like [D2L/S,D3, D4] antagonist yawning, which were insensitive to antagonism by haloperidol to identify any characteristic “ethogram,” in CP-293,019, L-745,870, or haloperidol. These findings fail terms of individual topographies of behavior within the to indicate any “ethogram” for selective manipulation of D4 natural rodent repertoire, as evaluated using ethologically receptor function at the level of the interaction between based approaches. Among the D4 antagonists, neither motoric and psychological processes in sculpting behavioral L-745,870 (0.0016–1.0 mg/kg) nor Ro 61-6270 (0.2–25.0 topography over habituation of exploration through to mg/kg) influenced any behavior; whereas, CP-293,019 quiescence and focus attention on social, cognitive, or other (0.2–25.0 mg/kg) induced episodes of nonstereotyped levels of examination. sniffing, sifting, and vacuous chewing; there were no [Neuropsychopharmacology 22:538–544, 2000] consistent effects on responsivity to the D2-like agonist RU © 2000 American College of Neuropsychopharmacology. 24213. Among the putative D4 agonists, CP-226,269 (0.2– Published by Elsevier Science Inc.
  • Pharmaceuticals Appendix

    Pharmaceuticals Appendix

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1